Natera, Inc. (NASDAQ:NTRA) CEO Sells $1,323,614.83 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 9,563 shares of Natera stock in a transaction on Monday, March 31st. The shares were sold at an average price of $138.41, for a total value of $1,323,614.83. Following the sale, the chief executive officer now directly owns 212,541 shares of the company’s stock, valued at $29,417,799.81. This represents a 4.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total value of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The shares were sold at an average price of $165.87, for a total transaction of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total transaction of $12,958,888.41.

Natera Trading Down 0.5 %

NASDAQ:NTRA traded down $0.76 during midday trading on Tuesday, reaching $140.65. 1,583,711 shares of the stock traded hands, compared to its average volume of 1,370,306. The stock has a market capitalization of $19.01 billion, a P/E ratio of -79.91 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.23 and a current ratio of 4.39. The company has a fifty day moving average of $158.72 and a 200 day moving average of $151.35. Natera, Inc. has a 12 month low of $83.13 and a 12 month high of $183.00.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. The company had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. On average, research analysts predict that Natera, Inc. will post -1.49 EPS for the current year.

Institutional Investors Weigh In On Natera

A number of large investors have recently made changes to their positions in NTRA. Wilmington Savings Fund Society FSB bought a new position in shares of Natera during the third quarter valued at approximately $385,000. Everence Capital Management Inc. purchased a new position in Natera during the 4th quarter valued at $573,000. Smartleaf Asset Management LLC raised its holdings in Natera by 50.3% in the 4th quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock worth $104,000 after purchasing an additional 220 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in shares of Natera by 87.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 67,906 shares of the medical research company’s stock worth $8,621,000 after purchasing an additional 31,649 shares during the period. Finally, SeaBridge Investment Advisors LLC bought a new stake in shares of Natera during the 4th quarter valued at about $2,894,000. 99.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on the stock. Robert W. Baird lifted their price objective on shares of Natera from $183.00 to $188.00 and gave the stock an “outperform” rating in a report on Friday, February 28th. Morgan Stanley lifted their price target on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. The Goldman Sachs Group raised their price objective on Natera from $160.00 to $190.00 and gave the company a “buy” rating in a report on Tuesday, January 28th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Wednesday, March 19th. Finally, Sanford C. Bernstein increased their price target on shares of Natera from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Friday, January 10th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.